SNAI1 and nonpapillary renal cell carcinoma: Thus, IGFBP3 was the dominant therapeutic target of CVB and the suppression of the IGFBP3-AKT/STAT3/MAPK-Snail signalling pathway may be the underlying mechanism by which CVB exerts its antitumour effects on ccRCC.